Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The PREOPANC-3 study is a randomized, multicenter, phase 3 trial. Patients with resectable pancreatic cancer will be randomly assigned (1:1) to 8 cycles of neoadjuvant mFOLFIRINOX followed by surgery and 4 cycles of adjuvant mFOLFIRINOX (arm 1) or to upfront surgery followed by 12 cycles of adjuvant mFOLFIRINOX (arm 2). The primary objective of the trial is to determine whether perioperative mFOLFIRINOX improves overall survival compared with adjuvant mFOLFIRINOX in patients with resectable pancreatic cancer.
Epistemonikos ID: fb780c95160b4231efce1bfc86ddf73f4f8f7386
First added on: May 09, 2024